Physician profile
Katy Sutton
NPI 1356996573
$5,965.46
in general payments reported to CMS, 2019-2025
43 companies · $821 in 2025
The $821 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,904 · 2022: $752 · 2023: $507 · 2024: $982 · 2025: $821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,309.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,099.20 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $912.53 | 2021-2024 | |
| Amgen INC. | $515.10 | 2021-2025 | Krystexxa, Evenity |
| Neurocrine Biosciences, INC. | $250.76 | 2021-2025 | Ingrezza |
| Novartis Pharmaceuticals Corporation | $238.13 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.69 | 2022-2024 | Jardiance |
| Biogen, INC. | $201.15 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $147.62 | 2021 | |
| Sk Life Science, INC. | $145.74 | 2021 | |
| Madrigal Pharmaceuticals | $145.59 | 2025 | Rezdiffra |
| Amneal Pharmaceuticals LLC | $137.80 | 2021 | |
| Axonics, INC. | $134.35 | 2024 | Axonics |
| Forte Bio-Pharma LLC | $125.01 | 2025 | Prolate, Nalocet, Tanlor |
| Sanofi-Aventis U.S. LLC | $122.15 | 2025 | |
| Acorda Therapeutics, INC | $121.87 | 2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katy Sutton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.